tri-GalNAc-ASO

Target: tri-GalNAc-ASO targets sequence-complementary hepatic RNA through hepatocyte-directed GalNAc delivery.

Binding site: Its GalNAc cluster binds ASGPR carbohydrate-recognition domains on hepatocytes.

Mechanism of action: tri-GalNAc-ASO is not a conventional PROTAC but a targeted oligonucleotide delivery format for hepatocyte-selective RNA knockdown. The triantennary N-acetylgalactosamine cluster binds the asialoglycoprotein receptor on hepatocytes, promoting receptor-mediated endocytosis and intracellular delivery of the antisense oligonucleotide. Once released into the appropriate intracellular compartment, the ASO hybridizes to a complementary RNA sequence and can promote RNase H1-mediated degradation or steric modulation, depending on chemistry. This platform is useful for studying liver-restricted transcript depletion, receptor-mediated uptake, RNA target validation, and delivery-dependent pharmacology.

• Enhanced PROTAC Efficacy: tri-GalNAc-ASO can be utilized to improve the delivery and efficacy of PROTAC molecules by facilitating their targeted delivery to liver cells. This approach leverages the tri-GalNAc moiety's affinity for liver-specific receptors, enhancing the degradation of liver-associated proteins.

• Liver-Specific Protein Degradation: By incorporating tri-GalNAc-ASO, researchers can achieve targeted protein degradation in hepatic tissues. This application is critical for studying the role of specific proteins in liver diseases and understanding their degradation pathways.

• Synergistic Targeted Degradation: tri-GalNAc-ASO can be combined with PROTACs to enhance the selectivity and potency of protein degradation. This synergy is particularly useful for dissecting complex biological pathways where precise protein knockdown is required.

• Optimized Delivery for PROTACs: The tri-GalNAc-ASO platform offers a strategic advantage in delivering PROTACs specifically to hepatocytes, thus minimizing off-target effects and maximizing the degradation of proteins implicated in liver pathologies.